Skip to main content
. 2010 May 20;2010:264360. doi: 10.1155/2010/264360

Table 3.

Response to second-line chemotherapy according to pathology and regime.

Histology Chemo CR PR SD PD NA
Synovial Dox 1 (0.3%) 3 (0.8%) 1 (0.3%)
Ifos 1 (0.3%) 4 (1.1%) 2 (0.5%) 15 (4.0%) 1 (0.3%)
Dox/Ifos 1 (0.3%) 2 (0.5%) 1 (0.3%) 2 (0.5%)
Other 2 (0.5%) 4 (1.1%) 13 (3.4%)

Liposarcoma Dox 1 (0.3%) 1 (0.3%) 3 (0.8%) 2 (0.5%)
Ifos 2 (0.5%) 3 (0.8%) 14 (3.7%)
Dox/Ifos 5 (1.3%) 1 (0.3%)
Other 1 (0.3%) 5 (1.3%) 6 (1.6%)

Leiomyosarcoma Dox 1 (0.3%) 7 (1.8%) 12 (3.2%) 1 (0.3%)
Ifos 1 (0.3%) 4 (1.1%) 27 (7.1%) 2 (0.5%)
Dox/Ifos 1 (0.3%) 2 (0.5%)
Other 2 (0.5%) 14 (3.7%) 59 (15.6%)

Other: Dox 6 (1.6%) 23 (6.1%)
Ifos 1 (0.3%) 2 (0.5%) 11 (2.9%) 31 (8.2%) 2 (0.5%)
Dox/Ifos 6 (1.6%)
Other 2 (0.5%) 2 (0.5%) 11 (2.9%) 50 (13.2%) 2 (0.5%)

Dox: doxorubicin, Ifos: Ifosfamide, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not assessable.